Physician profile
Alan Steljes
NPI 1962489872
$3,952.52
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,698 · 2020: $555 · 2021: $239 · 2022: $43.36 · 2023: $800 · 2024: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,234 · Travel and Lodging: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,233.56 |
| Travel and Lodging | $183.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Respicardia, INC. | $860.21 | 2019-2024 | Remede System |
| Inspire Medical Systems, INC. | $668.86 | 2023-2024 | Inspire |
| Amgen INC. | $557.35 | 2019-2021 | |
| Amarin Pharma, INC. | $329.56 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $271.07 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.97 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $220.71 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $134.68 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $116.21 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $103.72 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $96.04 | 2019-2021 | |
| Pfizer INC. | $88.97 | 2019-2021 | |
| Lundbeck LLC | $46.88 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $44.82 | 2019 | |
| Impulse Dynamics (USA) INC. | $43.36 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $40.52 | 2020-2021 | |
| Medtronic Vascular, INC. | $25.92 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $22.86 | 2023 | Inpefa |
| Merck Sharp & Dohme LLC | $19.06 | 2024 | Verquvo |
| Tactile Systems Technology INC | $14.96 | 2020 | |
| Alnylam Pharmaceuticals INC. | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Steljes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.